Metropolis Healthcare Ltd

On a consolidated basis, profit after tax rose 33.7% YoY to Rs 42 crore in Q3FY26, compared with Rs 31 crore in Q3FY25. Revenue from operations increased 25.8% YoY to Rs 406 crore in Q3FY26, compared with Rs 323 crore in Q3FY25. Profit before exceptional item and tax stood at Rs 66 crore in Q3FY26, up 56.5% YoY, while the quarter included an exceptional charge of Rs 9 crore related to the impact of the new labour code. EBITDA stood at Rs 95 crore in Q3FY26, up 32.4% YoY from Rs 72 crore in Q3FY25. EBITDA margin expanded to 23.4% in Q3FY26 from 22.2% in the year-ago quarter, reflecting an improvement of 120 bps. Total cost increased by 23.9% YoY, rising to Rs 311 crore in Q3FY26 from Rs 251 crore in Q3FY25. Depreciation rose 14.3% YoY to Rs 32 crore from Rs 28 crore a year ago. Finance costs increased 50.0% YoY to Rs 6 crore from Rs 4 crore. Operationally, patient volumes and test volumes grew 14% YoY and 13% YoY, respectively, supported by steady demand trends, deeper penetration in Tier II and Tier III markets, and a favourable mix shift toward complex and specialised testing. B2C revenues grew 19% YoY, while B2B revenues increased around 35% YoY, driven by network expansion and improved service levels. TruHealth and Specialty portfolios recorded growth of around 37% YoY and 34% YoY, respectively. Revenue per test and revenue per patient rose 11% YoY and 10% YoY. North India contributed 17% of revenue, while Tier III cities posted 16% revenue growth and accounted for 24% of overall revenues. Recent acquisitions including Core Diagnostics, Scientific Pathology in Agra, Dr. Ahuja's Pathology and Imaging Center in Dehradun, and Ambika Pathology Laboratory in Kolhapur were integrated as planned. Meanwhile, the company's board approved a 3:1 bonus issue of equity shares. Metropolis Healthcare is India's second-largest pathology laboratory chain, offering diagnostic testing and related services across a nationwide network, with a strong presence in specialised and preventive healthcare diagnostics. Powered by Capital Market - Live

Net profit of Metropolis Healthcare rose 31.98% to Rs 41.39 crore in the quarter ended December 2025 as against Rs 31.36 crore during the previous quarter ended December 2024. Sales rose 25.76% to Rs 405.91 crore in the quarter ended December 2025 as against Rs 322.77 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales405.91322.77 26 OPM %23.3722.31 - PBDT98.1470.03 40 PBT66.2642.34 56 NP41.3931.36 32 Powered by Capital Market - Live

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 4 February 2026.Powered by Capital Market - Live

Metropolis Healthcare has allotted 9,960 equity shares under the Metropolis - Restrictive Stock Unit Plan, 2020 on 13 January 2026. Powered by Capital Market - Live

Metropolis Healthcare announced the launch of its Centre of Genomics, marking a significant step in scaling its long standing capabilities in advanced genomics, molecular diagnostics, precision medicine, and genomic research. The Centre of Genomics is designed to deliver clinically actionable genomic insights across the care continuum, supporting multiple high-impact clinical specialties. Over the years, Metropolis has built a strong foundation in advanced genomics, with a particular focus on precision oncology anchored by its Global Reference Laboratory in Mumbai. Following the integration of Core Diagnostics' specialised genomics laboratory in the Delhi NCR region, these complementary capabilities have been unified to operate as CAP-accredited national referral laboratories for genomics, forming the backbone of the Centre of Genomics. This integrated model brings together a broad portfolio of NGS-based assays, robust bioinformatics and interpretation capabilities, and deep scientific and clinical expertise. As part of the Centre's technology backbone, Metropolis has augmented its existing sequencing infrastructure with the deployment of Illumina's NovaSeq' X Series for research purposes. The NovaSeq' X system features Illumina's cutting-edge XLEAP-SBS' chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq' X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what is possible in genetic sequencing, enabling users to unlock discoveries and advancements that were previously beyond reach. Beyond the newly deployed NovaSeq' X Series, the Centre of Genomics is supported by an existing, multi-platform NGS infrastructure already operational across Metropolis' key genomics hubs. The Centre of Genomics brings together multidisciplinary teams of molecular pathologists, genomic scientists, researchers, bioinformaticians, and certified genetic counsellors to ensure that complex genomic data is translated into clear, reliable, and clinically meaningful insights for patient care.Powered by Capital Market - Live

Can Fin Homes Ltd, Tejas Networks Ltd, Linde India Ltd, Chalet Hotels Ltd are among the other stocks to see a surge in volumes on BSE today, 12 January 2026.Metropolis Healthcare Ltd recorded volume of 1.16 lakh shares by 10:46 IST on BSE, a 36.96 times surge over two-week average daily volume of 3127 shares. The stock lost 2.40% to Rs.1,878.55. Volumes stood at 1635 shares in the last session.Can Fin Homes Ltd recorded volume of 2.02 lakh shares by 10:46 IST on BSE, a 17.64 times surge over two-week average daily volume of 11451 shares. The stock lost 1.17% to Rs.879.25. Volumes stood at 13022 shares in the last session.Tejas Networks Ltd clocked volume of 8.25 lakh shares by 10:46 IST on BSE, a 13.5 times surge over two-week average daily volume of 61091 shares. The stock lost 11.20% to Rs.370.05. Volumes stood at 2.57 lakh shares in the last session.Linde India Ltd saw volume of 7313 shares by 10:46 IST on BSE, a 8.85 fold spurt over two-week average daily volume of 826 shares. The stock increased 4.48% to Rs.6,175.00. Volumes stood at 1283 shares in the last session.Chalet Hotels Ltd recorded volume of 3.02 lakh shares by 10:46 IST on BSE, a 8.37 times surge over two-week average daily volume of 36095 shares. The stock lost 1.72% to Rs.857.55. Volumes stood at 1.03 lakh shares in the last session.Powered by Capital Market - Live

Net profit of Metropolis Healthcare rose 13.22% to Rs 52.67 crore in the quarter ended September 2025 as against Rs 46.52 crore during the previous quarter ended September 2024. Sales rose 22.70% to Rs 429.19 crore in the quarter ended September 2025 as against Rs 349.79 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales429.19349.79 23 OPM %25.2225.70 - PBDT103.4388.21 17 PBT71.0361.40 16 NP52.6746.52 13 Powered by Capital Market - Live

Metropolis Healthcare announced that the Board of Directors of the Company at its meeting held on 4 November 2025, inter alia, have recommended the interim dividend of Rs 4 per equity Share (i.e. 200%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Metropolis Healthcare rose 10.34% to Rs 46.63 crore in the quarter ended September 2025 as against Rs 42.26 crore during the previous quarter ended September 2024. Sales rose 10.62% to Rs 355.71 crore in the quarter ended September 2025 as against Rs 321.57 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales355.71321.57 11 OPM %25.6825.51 - PBDT89.9080.88 11 PBT62.1154.87 13 NP46.6342.26 10 Powered by Capital Market - Live

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 4 November 2025.Powered by Capital Market - Live